chartexchange

Cupid’s Management Expects 123% Revenue Growth in FY27; Check Which Business Is Driving the Growth

Trade Brains | Oct 5, 2026 2:13 AM EDT

This Mid-Cap Healthcare Stock, engaged in manufacturing condoms, personal lubricants, IVD kits, and FMCG products, serving domestic and international markets with exports to over 125 countries, is in focus after raising its FY27 revenue guidance to over Rs. 800 crore and net profit guidance to more than Rs. 250 crore, as Q2 FY27 revenue is expected to cross Rs. 200 crore, supported by growth across key business segments.
Stock Price Movement:
With a market capitalization of Rs. 42,094.60 crore, the shares of Cupid Limited were currently trading at Rs. 316 per equity share, rising nearly 0.99 percent from its previous day’s closing price of Rs. 312.90 per equity share. Over the past year, the stock has provided massive positive returns of more than 619.21 percent.
On October 01, 2026, the shares of Cupid Limited traded at Rs. 316, showing a gain of around 12,904.12 percent compared to the price of Rs. 2.43 on July 07, 2023. For example, if someone had invested Rs. 10,000 in the company’s stock 3 years ago, it would have turned into around Rs. 13,00,412 (Rs. 13 Lakh).

Also read: Ethos Receives Buy Rating from Emkay Global; Check the Target

Cupid Raises FY27 Growth Outlook:
Cupid Limited is seeing strong business momentum in FY27, with Q2 FY27 revenue expected to cross Rs. 200 crore. The growth is being supported by steady performance across its key healthcare, personal care, and consumer businesses, along with improving demand in domestic and international markets.
Based on this momentum, the company has raised its FY27 revenue guidance to more than Rs. 800 crore, which is 123 percent higher than FY26 revenue of Rs. 358 crore, and net profit guidance to more than Rs. 250 crore, which is around 131 percent higher than FY26 net profit of Rs. 108 crore. The higher guidance reflects better business visibility, continued growth across its major segments, and the company’s expanding presence in both Indian and global markets.
Operational Highlights in Q2 FY27:
Cupid Limited has taken several important steps to strengthen its business during Q2 FY27. The company approved the conversion of up to 30 lakh warrants of Baazar Style Retail Limited into equity shares at Rs. 328.25 per share. It also received in-principle approval to set up a manufacturing facility in South Africa, which could help Cupid expand its presence across Africa and other international markets.
The proposed South African facility will follow an asset-light business model, combining Cupid’s manufacturing expertise with support from local partners. This approach is expected to help the company serve institutional customers and build a stronger presence in African markets. Cupid also strengthened its healthcare business by making an additional US$5 million follow-on investment in GII Healthcare Investment Limited.
Meanwhile, Cupid continues to expand its FMCG, healthcare and personal care businesses, supported by growing manufacturing capabilities. The company also gained greater market visibility after being included in BSE Group ‘A’, NIFTY Small Cap 250 and the FTSE Emerging Markets All Cap Index.
Future Expansion Strategy:
Cupid Limited plans to expand its domestic FMCG business by increasing distribution across modern trade, general trade and pharmacy channels. The company also aims to operationalise its Palava manufacturing facility, which will help increase production capacity and improve supply flexibility. At the same time, Cupid plans to broaden its healthcare and personal care portfolio through new products, regulatory approvals and wider commercialisation opportunities.
The company also plans to strengthen its international healthcare business by expanding institutional, government and private-market opportunities across different regions. The proposed South African manufacturing venture could create a regional base for wider international expansion. Cupid will also explore strategic healthcare partnerships and investments that complement its existing healthcare and personal care businesses and support long-term growth.
Revenue Growth Outlook (Medium-Term):
Cupid Limited has set ambitious revenue targets for the coming years, aiming to increase revenue from Rs. 358 crore in FY26 to Rs. 1,085 crore in FY28 and Rs. 1,500 crore in FY29. This represents growth of approximately 203 percent by FY28 and 319 percent by FY29, highlighting the company’s plans for significant business expansion.
The company expects revenue to grow at a CAGR of around 61 percent between FY26 and FY29. This growth outlook is supported by Cupid’s strategy to expand its presence across domestic and international markets while building a broader product and distribution network.
Key growth drivers include wider distribution across Bharat, higher consumer-product sales, and additional manufacturing capacity. Cupid also expects opportunities from global tenders, while expanding its international manufacturing and healthcare operations to support long-term growth.
Expanding Consumer Distribution:
Cupid Limited is expanding its consumer distribution network through a Rs. 331.53 crore investment in Baazar Style Retail. The partnership provides Cupid access to more than 280 stores, with the network expected to expand to over 500 stores within the next two to three years. This wider retail reach is expected to improve product availability and help Cupid connect with more consumers across India.
The initiative is expected to contribute around Rs. 150 crore in revenue in FY27, with the potential to increase to nearly Rs. 500 crore annually in the coming years. Alongside its distribution expansion, Cupid is also strengthening its brand positioning through its “Made in India with Japanese Quality” initiative. The initiative is supported by a collaboration with one of Asia’s oldest condom manufacturers, combining local manufacturing capabilities with Japanese quality standards.
Expanding Capacity and Global Markets
Cupid is expanding its manufacturing capabilities by developing premium latex-free nitrile condoms for global markets. Its dual-polymer production lines at the Palava facility will enable manufacturing of both latex and nitrile condoms in India. 
The 170,000 sq. ft. facility is expected to be commissioned next quarter and could support an annual capacity of around 1.25 billion male condoms and 125 million female condoms. Cupid has also received CE certification under European IVDR for its diagnostic test kits, supporting potential expansion into European markets.

Also read: EID Parry and 5 Other Sugar Stocks to Watch as Inventory Hits a Decade Low and Prices Rise

Company Overview:
Cupid Limited was established in 1993 and is a healthcare and consumer wellness company offering male and female condoms, personal lubricants, IVD kits, and consumer healthcare and FMCG products. The company exports to more than 125 countries, serving government, institutional, and private markets. 
Cupid is the first company globally to receive WHO/UNFPA prequalification for both male and female condoms. In India, it is expanding through modern trade, organised retail and pharmacy channels, while its upcoming Palava facility is expected to strengthen manufacturing capacity and meet rising domestic and international demand.
Recent Quarter Results:
Looking at the company's financial highlights, Cupid Limited's revenue has increased from Rs. 65 crore in Q1 FY26 to Rs. 157 crore in Q1 FY27, which has grown by 141.54 percent. The net profit has also grown by 193.33 percent from Rs. 15 crore in Q1 FY26 to Rs. 44 crore in Q1 FY27.
Cupid Limited’s revenue and net profit have grown at a CAGR of 20 percent and 31 percent, respectively, over the last five years. In terms of return ratios, the company's ROCE and ROE stand at 33.9 percent and 27.6 percent, respectively. Cupid Limited has an earnings per share (EPS) of Rs. 1.02, and its debt-to-equity ratio is 0.13x.
 

Read original article